Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Arcturus Therapeutics' Cystic Fibrosis mRNA Therapy Shows Mixed Results in Phase II Trial

Arcturus Therapeutics' Cystic Fibrosis mRNA Therapy Shows Mixed Results in Phase II Trial

Arcturus Therapeutics' experimental inhaled mRNA therapy for cystic fibrosis (CF) has yielded mixed results in a Phase II clinical trial, leading to a significant drop in the company's stock price. The therapy, ARCT-032, failed to demonstrate meaningful lung function improvements but showed potential in reducing mucus volume in some patients.

NoahAI News10/24/2025
Alkermes to Acquire Avadel in $2.1B Deal, Expanding Sleep Medicine Portfolio

Alkermes to Acquire Avadel in $2.1B Deal, Expanding Sleep Medicine Portfolio

Alkermes plc has announced plans to acquire Avadel Pharmaceuticals in a deal valued at up to $2.1 billion, marking a significant expansion into the sleep medicine market. The acquisition will bring Avadel's narcolepsy drug Lumryz under Alkermes' fold, providing an immediate revenue boost and laying the groundwork for the potential launch of Alkermes' own narcolepsy candidate, alixorexton.

NoahAI News10/24/2025
Ventyx Biosciences' NLRP3 Inhibitor Shows Promise for Cardiovascular Disease

Ventyx Biosciences' NLRP3 Inhibitor Shows Promise for Cardiovascular Disease

Ventyx Biosciences, a San Diego-based drug company, has reported significant positive results from a mid-stage trial of its experimental drug VTX3232, an NLRP3 inhibitor. The study's findings have sparked investor interest and could potentially reshape the landscape of cardiovascular disease treatment.

NoahAI News10/24/2025
Galderma Commits $650M to US Manufacturing as Nemluvio Sales Soar

Galderma Commits $650M to US Manufacturing as Nemluvio Sales Soar

Galderma, the Swiss dermatology specialist, has announced a significant investment in US-based manufacturing, pledging to spend over $650 million through 2030. This move comes as the company reports booming sales of its newly approved drug Nemluvio and record-breaking revenue figures for the year.

NoahAI News10/24/2025
Regeneron Halts Development of CAR-T Therapy in Lymphoma Trial

Regeneron Halts Development of CAR-T Therapy in Lymphoma Trial

Regeneron Pharmaceuticals has announced the discontinuation of its CAR-T candidate bbT369, marking a significant setback in the company's cell therapy program. The decision comes amid a challenging landscape for cell therapies in the pharmaceutical industry.

NoahAI News10/24/2025
Innovative Wearable Technology Aims to Tackle Postpartum Hemorrhage

Innovative Wearable Technology Aims to Tackle Postpartum Hemorrhage

Armor Medical, a startup co-founded by Kelsey Mayo, Christine O'Brien, and Leo Shmuylovich, is developing a groundbreaking wearable device to detect early signs of postpartum hemorrhage. The company's innovative approach has garnered significant attention in the medical technology sector, including a recent grand prize win at MedTech Innovator's Early Stage pitch competition.

NoahAI News10/24/2025
Cambrex Announces $120M Expansion Amid Potential Sale

Cambrex Announces $120M Expansion Amid Potential Sale

Cambrex, a leading contract development and manufacturing organization (CDMO), has revealed plans for a significant expansion of its U.S. operations, investing $120 million to boost capacity at its Iowa facility. This move comes as the pharmaceutical industry continues to prioritize onshoring and amid reports of a potential sale of the company.

NoahAI News10/24/2025
Solventum Appoints New Chief Commercial Officer, Reshapes Leadership

Solventum Appoints New Chief Commercial Officer, Reshapes Leadership

Solventum, the recently spun-off healthcare technology company from 3M, has announced a significant leadership change with the appointment of Heather Knight as its new Chief Commercial Officer (CCO). This move comes as part of a broader restructuring of the company's executive team and commercial strategy.

NoahAI News10/24/2025
Community Health Systems Beats Q3 Expectations, Signaling Positive Trend for Hospital Sector

Community Health Systems Beats Q3 Expectations, Signaling Positive Trend for Hospital Sector

Community Health Systems (CHS), a leading for-profit hospital system, has reported strong third-quarter results that surpassed Wall Street expectations. The company's performance, marked by significant year-over-year gains and positive shareholder earnings, sets an optimistic tone for the healthcare sector's earnings season.

NoahAI News10/24/2025
Leadership Shifts and Agency Appointments Mark Week of Change in Pharma Industry

Leadership Shifts and Agency Appointments Mark Week of Change in Pharma Industry

In a week of significant leadership transitions, the pharmaceutical industry has seen notable shifts across multiple organizations, from biotech startups to government agencies. These changes signal ongoing evolution in the sector, with experienced executives taking on new challenges and fresh faces entering key roles.

NoahAI News10/24/2025
Inhibrx's Ozekibart Shows Promise in Rare Bone Cancers, Eyes FDA Submission

Inhibrx's Ozekibart Shows Promise in Rare Bone Cancers, Eyes FDA Submission

Inhibrx Biosciences has announced promising results for its antibody therapy ozekibart in treating rare bone cancers, setting the stage for a potential FDA submission in 2026. The San Diego-based biotech reported significant progress in both chondrosarcoma and Ewing sarcoma trials, marking a potential breakthrough in areas with limited treatment options.

NoahAI News10/24/2025
Lonza's Biologics Business Drives Growth, Fueled by Vacaville Acquisition

Lonza's Biologics Business Drives Growth, Fueled by Vacaville Acquisition

Swiss contract development and manufacturing organization (CDMO) Lonza has reported continued growth in the third quarter of 2025, with its recently acquired Vacaville, California biologics site playing a pivotal role in the company's sales rebound. The firm's strategic moves and market positioning have set the stage for a strong second half of the year, as it continues to navigate the post-COVID pharmaceutical landscape.

NoahAI News10/24/2025
«1...91011...67»